Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome
- PMID: 22036940
- DOI: 10.1093/ndt/gfr581
Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome
Abstract
Background: Nephrotic syndrome (NS) is a clinical state characterized by massive proteinuria and excessive fluid retention. The effects of early versus late treatment with low or high doses of oral everolimus, a mammalian target of rapamycin inhibitor, on proteinuria in NS have not been previously described.
Methods: The effects of early treatment (2 days prior to NS induction) versus late treatment (beginning 2 weeks following the establishment of NS) with a low (20 mg/L) or high (100 mg/L) dose of everolimus for 5-7 weeks on proteinuria and nephrin/podocin abundance were assessed in male adult SD rats with adriamycin-induced NS.
Results: Adriamycin caused a significant increase in daily and cumulative proteinuria throughout the experimental period. Early, and to a lesser extent late treatment, with a low dose of everolimus, significantly decreased both daily and cumulative proteinuria and improved renal function. The anti-proteinuric effects of low-dose everolimus were associated with restoration of the disruptive glomerular nephrin/podocin abundance. In contrast, administration of a high dose of everolimus resulted in a decrease in proteinuria in NS rats, subsequently to deterioration of renal function.
Conclusions: Early, and to a lesser extent late treatment, with a low but not a high dose of everolimus is effective in reducing proteinuria in nephrotic rats. The mechanism may be via nephrin/podocin protection.
Similar articles
-
Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.Am J Physiol Renal Physiol. 2005 Oct;289(4):F880-90. doi: 10.1152/ajprenal.00451.2004. Epub 2005 Jun 7. Am J Physiol Renal Physiol. 2005. PMID: 15942045
-
Qi-Dan Fang ameliorates adriamycin-induced nephrotic syndrome rat model by enhancing renal function and inhibiting podocyte injury.J Ethnopharmacol. 2014 Feb 12;151(3):1124-1132. doi: 10.1016/j.jep.2013.12.028. Epub 2014 Jan 3. J Ethnopharmacol. 2014. PMID: 24389029
-
Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.Am J Physiol Renal Physiol. 2008 Mar;294(3):F628-37. doi: 10.1152/ajprenal.00524.2007. Epub 2007 Dec 19. Am J Physiol Renal Physiol. 2008. PMID: 18094029
-
The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update.Inflamm Res. 2015 May;64(5):287-301. doi: 10.1007/s00011-015-0813-1. Epub 2015 Mar 19. Inflamm Res. 2015. PMID: 25788426 Review.
-
Rodent models to study sodium retention in experimental nephrotic syndrome.Acta Physiol (Oxf). 2022 Jul;235(3):e13844. doi: 10.1111/apha.13844. Epub 2022 May 26. Acta Physiol (Oxf). 2022. PMID: 35569011 Review.
Cited by
-
Effect of meloxicam (cyclooygenase-2 inhibitor) versus vitamin D3 (cholecalciferol) as ameliorating agents of progressive doxorubicin-induced nephrotoxicity in rats.Anat Cell Biol. 2020 Jun 30;53(2):169-182. doi: 10.5115/acb.19.231. Anat Cell Biol. 2020. PMID: 32647085 Free PMC article.
-
Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats.Iran J Pharm Res. 2018 Fall;17(4):1413-1419. Iran J Pharm Res. 2018. PMID: 30568699 Free PMC article.
-
Oxidative/Nitrative Stress and Inflammation Drive Progression of Doxorubicin-Induced Renal Fibrosis in Rats as Revealed by Comparing a Normal and a Fibrosis-Resistant Rat Strain.PLoS One. 2015 Jun 18;10(6):e0127090. doi: 10.1371/journal.pone.0127090. eCollection 2015. PLoS One. 2015. PMID: 26086199 Free PMC article.
-
Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α.Front Immunol. 2022 Jan 24;12:753412. doi: 10.3389/fimmu.2021.753412. eCollection 2021. Front Immunol. 2022. PMID: 35140705 Free PMC article.
-
Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats.EJNMMI Res. 2020 Apr 25;10(1):41. doi: 10.1186/s13550-020-00628-y. EJNMMI Res. 2020. PMID: 32335736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous